KMT Hepatech's Corporate Minority Round

KMT Hepatech raised a round of funding on November 24, 2017. Investors include PhoenixBio.

KMT Hepatech provides in vivo research services utilizing a proprietary platform technology of the chimeric mouse model with a highly humanized liver (up to 95% of stable human hepatocyte engraftment)…

Articles about KMT Hepatech's Corporate Minority Round: